mifepristone has been researched along with Carcinoma, Anaplastic in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 3 (30.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, MJ; Lu, ZZ; Yan, L; Zhang, H; Zhang, XH; Zhao, XX | 1 |
| Glazer, RI; Kopelovich, L; Lu, J; Upadhyay, G; Yuan, H | 1 |
| Bonafé, N; Chambers, SK; Flick, M; Savlu, A; Toy, EP; Zeiss, C; Zheng, W | 1 |
| Bamberger, AM; Briese, J; Erdmann, I; Götze, J; Nollau, P; Schulte, HM; Wagener, C | 1 |
| Joosten, JW; Kloosterboer, HJ; Schoonen, WG | 1 |
| Bartholomew, JS; Burt, DJ; Chengang, J; Garrido, F; Glenville, S; Ruiz-Cabello, F; Sarkar, S; Stanley, MA; Stern, PL | 1 |
| Arcuri, F; Carducci, A; Cintorino, M; Paulesu, L; Ricci, C; Runci, Y; Sestini, S | 1 |
| Aikins, JA; Paulson, J; Rocereto, TF; Saul, HM | 1 |
| Monet, JD; Thomas, M | 1 |
| Edwards, DP; Elashry-Stowers, D; Speers, WC; Zava, DT | 1 |
1 trial(s) available for mifepristone and Carcinoma, Anaplastic
| Article | Year |
|---|---|
Phase II study of mifepristone (RU486) in refractory ovarian cancer.
Topics: Adult; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; CA-125 Antigen; Carcinoma; Cisplatin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Hormone Antagonists; Humans; Mifepristone; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2000 |
9 other study(ies) available for mifepristone and Carcinoma, Anaplastic
| Article | Year |
|---|---|
[Mifepristone inhibites the migration of endometrial cancer cells through regulating H19 methylation].
Topics: Antigens, CD; Cadherins; Carcinoma; Cell Line, Tumor; Cell Movement; DNA Methylation; Down-Regulation; Endometrial Neoplasms; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; HMGA2 Protein; Humans; Mifepristone; Promoter Regions, Genetic; RNA, Long Noncoding; RNA, Messenger; Up-Regulation; Vimentin | 2016 |
The chemopreventive effect of mifepristone on mammary tumorigenesis is associated with an anti-invasive and anti-inflammatory gene signature.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Agents, Hormonal; Carcinogens; Carcinoma; Chemoprevention; Drug Evaluation, Preclinical; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Hormone Antagonists; Inflammation; Mammary Neoplasms, Experimental; Mice; Mice, Transgenic; Microarray Analysis; Mifepristone; Neoplasm Invasiveness; Paired Box Transcription Factors; PAX8 Transcription Factor | 2012 |
Correlation of tumor phenotype with c-fms proto-oncogene expression in an in vivo intraperitoneal model for experimental human breast cancer metastasis.
Topics: Animals; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Dexamethasone; Disease Models, Animal; Female; Gene Expression; Hormone Antagonists; Humans; Mice; Mice, Inbred BALB C; Mice, SCID; Mifepristone; Peritoneal Cavity; Phenotype; Proto-Oncogene Mas; Receptor, Macrophage Colony-Stimulating Factor; Up-Regulation | 2005 |
Stimulation of CEACAM1 expression by 12-O-tetradecanoylphorbol-13-acetate (TPA) and calcium ionophore A23187 in endometrial carcinoma cells.
Topics: Anti-Bacterial Agents; Antigens, CD; Calcimycin; Carcinoma; Cell Adhesion Molecules; Endometrial Neoplasms; Estradiol; Female; Hormone Antagonists; Humans; Interferon-gamma; Medroxyprogesterone Acetate; Mifepristone; Phorbol Esters; Protein Kinase C; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2006 |
Effects of two classes of progestagens, pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumor cells: II. T47D cell lines.
Topics: Breast Neoplasms; Carcinoma; Cell Division; Desogestrel; Dose-Response Relationship, Drug; Estradiol; Estrenes; Estrogen Antagonists; Female; Furans; Humans; Levonorgestrel; Medroxyprogesterone Acetate; Mifepristone; Nandrolone; Norethindrone; Norpregnenes; Pregnanes; Pregnenediones; Progesterone; Promegestone; Tumor Cells, Cultured | 1995 |
Integration of high-risk human papillomavirus DNA is linked to the down-regulation of class I human leukocyte antigens by steroid hormones in cervical tumor cells.
Topics: Carcinoma; DNA, Viral; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Viral; Histocompatibility Antigens Class I; Hormone Antagonists; Humans; Hydrocortisone; Mifepristone; Papillomaviridae; Progesterone; Tumor Cells, Cultured; Uterine Cervical Neoplasms; Virus Integration | 1997 |
Progestin regulation of 11beta-hydroxysteroid dehydrogenase expression in T-47D human breast cancer cells.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Breast Neoplasms; Carcinoma; Corticosterone; Dose-Response Relationship, Drug; Estradiol; Estrone; Female; Gene Expression Regulation, Enzymologic; Humans; Hydroxysteroid Dehydrogenases; Medroxyprogesterone Acetate; Mifepristone; NAD; Progesterone Congeners; Progestins; RNA, Messenger; Tumor Cells, Cultured | 2000 |
Combined effects of RU486 and tamoxifen on the growth and cell cycle phases of the MCF-7 cell line.
Topics: Breast Neoplasms; Carcinoma; Cell Count; Cell Cycle; Cell Division; DNA, Neoplasm; Drug Combinations; Humans; Mifepristone; Osmolar Concentration; Tamoxifen; Tumor Cells, Cultured | 1992 |
Immunocytochemical localization of progesterone receptors in breast cancer with anti-human receptor monoclonal antibodies.
Topics: Antibodies, Monoclonal; Antibody Specificity; Breast Neoplasms; Carcinoma; Cell Nucleus; Cytosol; Estrenes; Female; Humans; Immunohistochemistry; Mifepristone; Molecular Weight; Promegestone; Receptors, Estrogen; Receptors, Glucocorticoid; Receptors, Progesterone | 1988 |